Form 4: Immunocore Holdings SVP, Finance & CAO, John Goll, Reports Stock Option and Restricted Share Unit Grants

John Goll, SVP, Finance & CAO of Immunocore Holdings plc, reports the acquisition of stock options and restricted share units.

Summary

• On February 17, 2025, John Goll, SVP, Finance & CAO of Immunocore Holdings plc, was granted employee share options for 14,802 ordinary shares at an exercise price of $29.60.
• These options vest over time, with 25% vesting on February 17, 2026, and the remaining 75% vesting quarterly thereafter, contingent upon continuous service.
• Goll also acquired 5,405 restricted share units (RSUs), each representing a contingent right to receive one ordinary share.
• These RSUs vest in four equal annual installments starting February 17, 2026, also subject to continuous service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices that align management interests with shareholder value. There are no immediate financial implications, but it signals confidence in the executive's continued contribution.

Positives

• The grant of stock options and RSUs aligns the executive's interests with those of the shareholders.
• The vesting schedules incentivize long-term commitment and performance.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the options and RSUs.

Industry Context

This type of equity compensation is common in the biotechnology industry to attract and retain key personnel and align their interests with the long-term success of the company.

Comparison to Industry Standards

• Equity compensation packages, including stock options and RSUs, are standard practice among publicly traded biotechnology companies like Immunocore.
• Companies such as Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize similar compensation strategies to incentivize their executives.
• The vesting schedules described are typical, with vesting periods ranging from three to five years, contingent upon continued employment.

Stakeholder Impact

• Shareholders: The grants align management's interests with shareholder value.
• Employees: The grants can boost morale and incentivize performance.
• Company: The grants help retain key personnel.

Key Dates

Keywords

Immunocore Holdings, John Goll, stock options, restricted share units, RSUs, Form 4, beneficial ownership, equity securities, vesting